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on these ﬁndings, a framework consisting of key characteristics of an AED scheme 
was developed and, subsequently, applied to an inventory of existing AED schemes, 
compiled through a comprehensive review of relevant peer-reviewed and ‘grey’ litera-
ture available as of August 2009. RESULTS: The framework contained 11 character-
istics of AED schemes grouped into 3, sequential categories: 1) System level (Decision 
problem; Objective; Engagement; Evaluation); 2) Organisational (Governance; 
Financing); and 3) Research design (Scope; Level of Operation; Test Criterion; Test 
Implementation; Response to Test Result). It was applied to the inventory in the form 
of a checklist, similar to other critical appraisal tools. In general, information found 
for each of the schemes was limited and did not address questions comprising the 
checklist. CONCLUSIONS: Information upon which to evaluate AED schemes is 
sparse, yet necessary for moving forward with efforts to ensure their use represents 
value for money.
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OBJECTIVES: This study examines the availability of and eligibility requirements for 
pharmaceutical patient assistance programs (PAPs) for the most commonly prescribed 
medications in the United States. METHODS: RxAssist.org, an electronic database of 
PAPs, was utilized to collect information on the availability (brand and/or generic) 
and eligibility (citizenship, permanent residency, insurance, and income limits) for each 
of the “Top 200 drugs by dispensed prescriptions” for 2008. Pharmaceutical compa-
nies were contacted directly or their websites were searched when additional clariﬁca-
tions were needed. Chi-square analyses were used to assess for differences in eligibility 
requirements by drug availability (brand or generic). RESULTS: Of 136 unique chemi-
cal entities, 111 (81.6%) of these drugs were available in RxAsisst.org. 69 (62.2%) 
of the available drugs were brand only, 29 (26.1%) generic only and 13 (11.7%) had 
both brand/generic forms. There were differences found in PAP eligibility requirements 
for citizenship (p < 0.001), permanent residency (p < 0.001), and private insurance 
status (p < 0.001) by drug availability (brand versus generic), but not for income limits 
(p = 0.051). Some programs allow Medicare Part D patients to apply for PAP; 
however, each claim is evaluated on case-to-case basis. CONCLUSIONS: Both brand 
and generic drugs are widely available to low-income applications through PAPs, but 
results suggest that U.S. citizenship and permanent residency are more likely to be 
required by PAPs for brand versus generic drugs. PAPs also provide some options for 
the underinsured—those with either private insurance or Medicare Part D coverage.
PHP16
LOW SOCIOECONOMIC STATUS IS A RISK FACTOR FOR CPAP 
ACCEPTANCE AMONG ADULT OSAS PATIENTS REQUIRING 
TREATMENT
Simon-Tuval T1, Reuveni H1, Greenberg-Dotan S1, Oksenberg A2, Tal A3, Tarasiuk A3
1Ben-Gurion University, Beer-Sheva, Israel, 2Loewenstein Hospital-Rehabilitation Center, 
Ra’anana, Israel, 3Soroka University Medical Center, Beer-Sheva, Israel
OBJECTIVES: To evaluate whether socioeconomic status (SES) plays a role in the 
patient’s decision to accept (purchase) continuous positive airway pressure (CPAP) 
treatment for obstructive sleep apnea syndrome (OSAS) (according to the Israeli 
National Health Insurance Law, purchasing CPAP treatment requires an out-of-pocket 
payment). METHODS: Cross-sectional prospective study in the University-afﬁliated 
Sleep Disorder Center in Beer-Sheva, Israel. Adult patients (age > 18 years), suspected 
of having OSAS, were consecutively recruited between March 2007 and December 
2007. Questionnaires were completed prior to diagnosis to elicit socioeconomic status, 
sleeping habits, and access to sources of information on OSAS and its treatments. At 
the conclusion of the adaptation period, a second questionnaire was completed to 
explore the reasons for commencing or declining treatment. RESULTS: Among the 
newly diagnosed (polysomnographically) adult OSAS patients, 162 required CPAP 
and underwent attendant titration and a 2-week adaptation period. Only 40% of these 
patients (n = 65) decided to purchase CPAP therapy. They were older, and typically 
they had higher apneahypopnea indexes (AHIs) and higher income levels than the 
patients who declined CPAP treatment. Multivariate logistic regression (adjusting for 
body mass index and Epworth Sleepiness Scale) revealed that whether a patient pur-
chased CPAP was determined by (OR, 95% CI): income level (2.4; 1.2–4.6), age (+1 
year) (1.07; 1.01–1.1), AHI (≥ 35 vs. < 35 events/hr) (4.2, 1.4–12.0), receiving positive 
feedback about the experiences of family or friends with CPAP (2.9, 1.1–7.5), and 
sleeping separate from spouse (4.3, 1.4–13.3). CONCLUSIONS: In addition to the 
already known determinants of CPAP acceptance, patients with low SES were less 
receptive to CPAP treatment than those with higher SES. CPAP support and patient 
education programs should be tailored for low SES people in order to increase rates 
of treatment initiation and adherence.
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OBJECTIVES: There is a lack of understanding and empirical basis regarding what 
factors are important in the Medicare National Coverage Determination (NCD) deci-
sion making process. The objective of this study was to determine what factors predict 
favorable coverage decisions. METHODS: NCDs from 1999 through 2007 were 
reviewed using publicly available decision memoranda posted on the CMS website (n 
= 140). Data abstracted from decision memoranda were supplemented with cost-
effectiveness information identiﬁed from an independent literature review. When a 
decision memo included coverage decisions for multiple technologies or indications, 
an entry was made for each coverage decision in the memorandum. The United States 
Preventative Services Task Force (USPSTF) guidelines were used to grade the support-
ing clinical evidence. We created a dataset with the following variables: quality of 
supporting clinical evidence; availability of alternative interventions; cost-effectiveness 
of intervention; intervention type, and coverage requestor. Logistic regression was 
used to determine what variables predicted favorable coverage. RESULTS: Good 
quality supporting clinical evidence was associated with an odds ratio (OR) of favor-
able coverage (95% CI) of 12.74 (3.02–53.74). Interventions estimated to be domi-
nant, i.e. less costly and more effective, or have an estimate of cost-effectiveness of < 
$50k per QALY were associated with an OR of 18.86 (4.62–77.00) and 3.91 (1.00–
15.40) respectively. Availability of alternative interventions for the same indication 
was associated with a decreased likelihood of coverage with an OR of 0.01 (0.03–
0.33). Type of intervention, and coverage requestor were not signiﬁcant predictors. 
CONCLUSIONS: The ﬁndings suggest that good quality supporting clinical evidence 
and favorable estimates of cost-effectiveness predict favorable CMS coverage deci-
sions. The availability of alternative interventions for the same indication reduced the 
likelihood of a favorable coverage decision. The ﬁndings indicate that Medicare’s 
coverage process is evidence and value-based, though more research is needed on the 
impact of decisions.
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OBJECTIVES: To evaluate the percent of patients reaching the coverage gap and 
catastrophic phase and their pharmacy and medical utilization for the treatment of 
common conditions (asthma, COPD, coronary artery disease, depression, diabetes, 
hyperlipidemia, hypertension (HTN), heart failure (HF)) among patients enrolled in 
Medicare Advantage with Part D coverage (MAPD). METHODS: Retrospective 
claims analysis using medical/pharmacy claims and enrollment data from a large 
National US Plan offering MAPD beneﬁts. Patients with full-year enrollment in 2007 
and ≥1 select condition based on claims in 2006 were identiﬁed. Phase transitions 
were based on pharmacy expenditures and low income subsidy and dually eligible 
patients were excluded. Outcomes included the proportion of patients ﬁlling any 
medication per national guidelines, proportion of days covered (PDC) for patients 
ﬁlling ≥1, compliance (MPR) for patients ﬁlling ≥2 and medical utilization/costs overall 
and by phase. RESULTS: The percentage of patients reaching the coverage gap ranged 
by condition from 18%–36% with 2%–6% reaching catastrophic. For all conditions, 
pharmacy utilization was lower in the coverage gap however, patients ﬁlling medica-
tions in the gap spent on average 8%(HTN) to 160%(depression) more out-of-pocket 
compared to their coinsurance phase. As with pharmacy utilization, medical also 
decreased during the coverage gap. Overall, the proportion of patients ﬁlling any 
acceptable medication for their condition ranged from 40%(COPD) to 95%(HF). The 
proportion of those with ≥80% PDC ranged from asthma(19%) to HF(76%) while 
compliance rates for patients reﬁlling (MPR ≥ 80%) ranged from Asthma(37%) to 
HF(87%). CONCLUSIONS: A fairly high percent of patients reached the coverage 
gap in 2007 and incurred substantially larger out-of-pocket expenses. Once in the gap, 
both medical and pharmacy utilization on average decreased. Medication compliance/
persistence was less than optimal overall and with up to one-third of patients reaching 
the gap there is further potential for reduced quality care that could negatively impact 
the health of an aging population.
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OBJECTIVES: This study examined the prevalence of antidepressant drug use and 
factors associated with their use among elderly nursing home residents in the Unites 
States using the 2004 National Nursing Home Survey (NNHS) data. METHODS: The 
study involved analysis of prescription and resident ﬁles of a nationally representative 
sample of residents aged ≥65 years from the 2004 NNHS data. The analysis focused 
on the prescribing of any antidepressant, including selective serotonin reuptake inhibi-
tors (SSRI), tricyclic antidepressants (TCAs), serotonin modulators, serotonin-norepi-
nephrine reuptake inhibitor (SNRI), MAO (Monoamine oxidase) inhibitors and 
‘other’ antidepressants such as mirtazapine and bupropion. A descriptive weighted 
analysis was performed to examine the prevalence patterns. Multiple logistic regres-
